OS Fund Q1 2019 Update
Posted: April 2019
OS Fund II Update
OS Fund II is on track to close in early spring. Please direct any questions to Eva Baczynska (Eva@TheAsterGroup.com) or Jeff Klunzinger (firstname.lastname@example.org).
GINKGO BIOWORKS LAUNCHES FOOD PROTEIN COMPANY
Ginkgo Bioworks launched a new company, Motif Ingredients, raising $90M, that is built on Ginkgo’s platform to create the future of food—protein. Motif Ingredients will use Ginkgo’s Foundry to discover and develop new proteins for food that can be made via fermentation, not animal agriculture. In the very near future, your hamburger will be as delicious as it is sustainable.
PIVOT BIO RAISES $70M TO REPLACE FERTILIZER WITH GENETICALLY MODIFIED BACTERIA
Pivot Bio raised $70 million for its nitrogen-fixing bacteria. The funding follows the completion of 11,000 trials where its product yielded better harvests than chemical fertilizer in 13 different US states. Synthetically produced nitrogen fertilizer is a major water pollutant, releasing greenhouse gas that’s 300 times more potent than carbon dioxide. With its latest round of funding, Pivot Bio will introduce a product for US corn farmers, before moving on to other crops like wheat and rice.
CATALOG DNA AND PIVOT BIO MADE FAST COMPANY’S “MOST INNOVATIVE COMPANIES OF 2019” LIST
JUST EGG GOES NATIONWIDE WITH WHOLE FOODS AND SPROUTS
In April, Whole Foods will be rolling out JUST Egg 2.0 nationwide. Sprouts Farmers Market is doing the same this month. Sales of JUST Egg are now well past the equivalent of 4 million conventional eggs. According to the company, they are already outselling liquid eggs head-to-head in over 5,000 stores, including Albertsons and Safeway.
TWOXAR PARTNERS WITH 1ST BIO ON GLIOBLASTOMA TREATMENTS
In its third biopharma deal since closing a fundraising round last spring, TwoXAR has partnered with South Korea’s 1ST Biotherapeutics to discover and develop new treatments for glioblastoma, the most aggressive kind of brain cancer. Under the deal, twoXAR will use its AI platform to identify drug candidates, both partners will select promising candidates and 1ST Bio will develop them.
OS Fund companies are in market, improving the world and delivering returns, right now. OS Fund invests in entrepreneurs using applied intelligence to commercialize breakthrough discoveries in genomics, synthetic biology, diagnostics, new materials, and data and energy. We seek out platform enabling technologies that accelerate discovery and commercialization. We never invest in a single molecule, model or algorithm. We do hard science investing with technology level risk.
Sign up for the OS Fund newsletter
Return to Newsletters